KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Operating Income (2018 - 2025)

Vir Biotechnology's Operating Income history spans 8 years, with the latest figure at -$47.9 million for Q4 2025.

  • For Q4 2025, Operating Income rose 59.09% year-over-year to -$47.9 million; the TTM value through Dec 2025 reached -$479.3 million, up 18.37%, while the annual FY2025 figure was -$479.3 million, 18.37% up from the prior year.
  • Operating Income for Q4 2025 was -$47.9 million at Vir Biotechnology, up from -$173.4 million in the prior quarter.
  • Across five years, Operating Income topped out at $1.0 billion in Q1 2022 and bottomed at -$231.3 million in Q3 2024.
  • The 5-year median for Operating Income is -$139.3 million (2023), against an average of -$24.8 million.
  • The largest YoY upside for Operating Income was 739.1% in 2022 against a maximum downside of 469.11% in 2022.
  • A 5-year view of Operating Income shows it stood at $571.8 million in 2021, then tumbled by 126.32% to -$150.5 million in 2022, then grew by 7.63% to -$139.0 million in 2023, then increased by 15.73% to -$117.2 million in 2024, then skyrocketed by 59.09% to -$47.9 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Operating Income are -$47.9 million (Q4 2025), -$173.4 million (Q3 2025), and -$118.4 million (Q2 2025).